Controlled double-blind comparative trial with fluprednylidene acetate cream and its base.
The effect of combined therapy with fluprednylidene acetate cream applied once daily plus cream base of the same formulation twice daily was tested in controlled double-blind contralateral investigations carried out on 31 in-patients with skin diseases which react to corticoids. Comparison with the 3 times daily application of the cream containing fluprednylidene and the 3 times daily application of a cream containing betamethasone 17-valerate did not show any differences in the result of treatment which was good to very good in each case within a 15-day trial period. No side effects were determined. The combined treatment with fluprednylidene acetate cream (once daily) and the cream base of the same formulation means that by economising on the use of the corticoid the risk involved in treatment is reduced and a therapeutic concept can be propounded which is suitable for all individual circumstances because the cream base used is kept constant.
D000085:Acetates; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005477:Fluprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005938:Glucocorticoids; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy; D008297:Male; D010392:Pemphigus / Q000188:drug therapy; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D014631:Valerates
D000085:Acetates; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D010919:Placebos; D014631:Valerates; D001623:Betamethasone; D005477:Fluprednisolone